# Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

> **NCT04295772** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 42 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** DOR/ISL

## Key facts

- **NCT ID:** NCT04295772
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-26
- **Primary completion:** 2021-12-21
- **Final completion:** 2023-01-25
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04295772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04295772, "Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04295772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*